Author

Hannah Majeski

Observed name: H. Majeski

Institution: BioTheryX (United States)

Observed institution: BioTheryX (United States)

OpenAlex ID: A5063238521

BTX-1188, a first-in-class dual degrader of GSPT1 and IKZF1/3, for treatment of acute myeloid leukemia (AML) and solid tumors.

2022 · Aparajita Hoskote Chourasia, Hannah Majeski, et al. · Journal of Clinical Oncology · 22

Characterization of BTX-9341, a bifunctional degrader of CDK4 and CDK6 for HR+/HER2- breast cancer and glioblastoma multiforme.

2024 · Hannah Majeski, Kirti Chahal, et al. · Journal of Clinical Oncology · 6

Abstract PS4-06-04: First-in-human Phase 1 study of BTX-9341, a CDK4/6 bifunctional degrader, as monotherapy and in combination with fulvestrant in patients with advanced and/or metastatic HR+/HER2- breast cancer - first emerging data

2026 · A. Patnaik, M. Block, et al. · Clinical Cancer Research · 1

Abstract PO5-05-02: Discovery of BTX-9341, a bifunctional degrader of CDK4 and CDK6 for HR+/HER2- breast cancer

2024 · Hannah Majeski, Akinori Okano, et al. · Cancer Research · 1

Abstract 6068: Discovery of BTX-9341, a bifunctional degrader of CDK4 and CDK6 for HR+/HER2- breast cancer

2024 · Hannah Majeski, Akinori Okano, et al. · Cancer Research · 1

Discovery of CDK4/6 bifunctional degraders for ER+/HER2- breast cancer.

2023 · Hannah Majeski, Akinori Okano, et al. · Journal of Clinical Oncology · 1

421RO Dose optimization of BTX-9341, a first-in-class CDK4/6 bifunctional degrader, in CDK4/6 inhibitor-pretreated HR+/HER2− advanced/metastatic breast cancer

2026 · M.P. Goetz, A. Patnaik, et al. · ESMO Open

Abstract P4-11-02: Characterization of BTX-9341, a bifunctional degrader of CDK4 and CDK6 for HR+/HER2- breast cancer

2025 · Hannah Majeski, Kirti Kandhwal Chahal, et al. · Clinical Cancer Research

Abstract 5702: BTX-9341, a bifunctional degrader of CDK4 and CDK6 for glioblastoma multiforme

2024 · Hannah Majeski, Kirti Chahal, et al. · Cancer Research

Abstract 1553: Discovery of CDK4/6 bifunctional degraders for ER+/HER2- breast cancer andtriple negative breast cancer

2023 · Hannah Majeski, Akinori Okano, et al. · Cancer Research

Works count: 10

Citation count: 32

H-index: 2

I10-index: 1